RT Journal Article
SR Electronic
T1 Safety of the newer class of opioid antagonists in pregnancy
JF Canadian Family Physician
JO Can Fam Physician
FD The College of Family Physicians of Canada
SP 631
OP 632
VO 60
IS 7
A1 Shirley Poon
A1 Anna Pupco
A1 Gideon Koren
A1 Pina Bozzo
YR 2014
UL http://www.cfp.ca/content/60/7/631.abstract
AB Question I have a patient recently confirmed to be 6 weeks pregnant. For the past 6 months she has been treated for an opioid addiction with buprenorphine-naloxone combination. Should I be concerned about her exposure to this drug combination up to this point of the pregnancy? Should I switch her medication to methadone now that she is pregnant? Answer The limited data on buprenorphine exposure during pregnancy show no increased risk of adverse outcomes in the newborn. There are limited data on naloxone exposure during pregnancy; however, oral use is not expected to be associated with an increased risk of adverse pregnancy outcomes. Physicians treating pregnant women or women who become pregnant while they are stable taking buprenorphine-naloxone treatment are advised to continue this treatment but to consider transition to buprenorphine monotherapy.